Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis

Bhavisha Patel, Joseph H. Butterfield, Catherine R. Weiler, Sunanda V. Kane

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The development and utilization of monoclonal antibodies (mAbs) have been of great interest in all fields of medicine. A substantial increase in the production and development of mAbs has occurred because these biologic agents are proving to be effective and less toxic given their targeted mechanism of action. However, data are limited on coadministration of two or more mAbs. With the increasing availability of mAbs and the comorbidities of some patients, assessment is needed of the ability to safely use multiple mAbs for an individual patient. Although the efficacy of coadministered mAbs may be inferred from their specific targets, we could find no literature reporting such a finding. Herein, we report our experience using two different classes of mAbs to treat hypereosinophilic syndrome and ulcerative colitis in a single patient.

Original languageEnglish (US)
Pages (from-to)300-303
Number of pages4
JournalMonoclonal Antibodies in Immunodiagnosis and Immunotherapy
Volume35
Issue number6
DOIs
StatePublished - Dec 1 2016

Keywords

  • drug interactions
  • gastroenterology
  • hematology

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis'. Together they form a unique fingerprint.

  • Cite this